Open Orphan (ORPH) announced on Thursday that it appointed a leading virology expert to its newly established advisory board to guide the company in providing coronavirus solutions.
The specialist pharmaceutical services company focused on orphan drugs and viral vaccine challenge study services, appointed Professor John Oxford and Open Orphan director Professor Brendan Buckley to the Advisory Board.
Open Orphan said the board was established to help it support product development for customers developing antivirals, vaccines and respiratory therapeutics.
The company said it will initially focus on guiding Open Orphan in the provision of solutions to the current Coronavirus outbreak.
Shares in Open Orphan were trading flat at 5.975p on Thursday after the announcement
Open Orphan completed a merger with AIM-listed hVIVO last month to create a European full pharma services company.
Open Orphan highlighted in a press release that it has Europe's only 24 bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London.
Professor John Oxford, who will Chair the Advisory Board, is a Professor at Queen Mary's University London and one of the world's leading experts on global diseases such as influenza, including bird flu, SARS, MERS and Coronavirus.
Professor Buckley is a doctoral graduate in Biochemistry from Oxford University with over 30 years’ experience in clinical research and previously served as Director of the Health Products Regulatory Authority of Ireland.
Follow News & Updates from Open Orphan here: